Document Type

Article

Publication Date

2-11-2025

Comments

This article is the author's final published version in Cephalalgia Reports, Volume 8, January-December 2025.

The published version is available at https://doi.org/10.1177/25158163241313123.

Copyright © The Author(s) 2025.

Abstract

Background: Mexiletine is used as a preventive medication for refractory chronic migraine (rCM) and to prolong migraine improvement following intravenous lidocaine infusion. However, published evidence supporting its use in migraine remains limited. This retrospective study describes the dosing, treatment duration, and adverse effects of mexiletine in a group of patients with rCM following lidocaine infusion. Methods: Electronic medical records were reviewed at the Jefferson Headache Center. Baseline pain intensity and monthly headache days were collected at baseline and up to 6 office visits within 1-year post-discharge. The duration of mexiletine treatment was evaluated for up to 40 months post-discharge. Results: The study included 329 rCM patients who were prescribed a daily dose of 450 mg. At the last follow-up, the median daily dose was 600 mg (450 mg–750 mg). Mexiletine was discontinued in 36.4% (120/329) of patients due to side effects and in 11.2% (37/329) due to insufficient treatment response. Conclusion: In our population, 37% (104/329) remained on mexiletine for over 500 days, indicating a favorable safety profile. While mexiletine can be safely administered in outpatient settings, its use should be reserved for patients with the most refractory cases unless stronger evidence supporting its efficacy in migraine becomes available.

Creative Commons License

Creative Commons License
This work is licensed under a Creative Commons Attribution-Noncommercial 4.0 License

Language

English

Download

Included in

Neurology Commons

Share

COinS